Hypothyroidism f ollowing hemith yroidectoniy f or benign nontoxic thyroid disease is an underappreciat ed ph enomenon. Up until recently, it was common pra cticefo r physicians to pla ce post-hemith yroidectonty patients on thyroid suppression therapy dur ing the immediate postoperative period. That pra ctice began to fa ll out offavor as a result of two developments: (1) the publication of data that put into ques tion the efficacy of levothyroxin e therapy fo r preventin g recurrent disease or thyroid growth and (2) a height ened awareness ofthe morbidity associated with levothyroxin e. We conducted a retrospective chart-review study of58 patients with benign nontoxi c thyroid disease who had undergone hemith yroidectomyf rom1 994 through 2003 at one institution. Of these 58 patients, 14 (24.1 %) had becom e hypothyroid af ter surgery, includin g 7 who had been so diagnose d 1 month postoperatively and 6 at 2 month s. The remaining 44 patients were euthyroid. The mean preoperati ve serum thyroid-stimulating hormone (TSH) levels in the hypothyroid and the euthy roid groups were 2.39 and 1.07 plll/ml, respectively-a statistically significant difference (p < 0.0001). A tissue diagnosis consistent with chronic inflammation (lymphocytic thyroiditis or Hashimoto s thyroiditi s) was fo und in 50.0% of the hypothyroid patients, compared with only 6.8 % of the euthyroid patients-again , a significant difference (p < 0.001). No significant difference was seen between the two groups with respect to age, sex, or the weig ht of the resected gland. We concl ude that hypothyroidism after From the Departmen t of Otolaryngo logy-Head and Neck Surgery (Dr.
hemithyroidectom y is not an unc ommon occurrence. Apparent risk factors include a high mean preoperative serum TSH level and tissue pathology consistent with chronic inflammation. It may be wise to foll ow patients with these identifiable risk f actors more closely durin g the postoperativeperiod; monitoring should include scheduled serial se rum TSH draws.
Introd uction
The development of hypoth yroidi sm following hemithyroidectomy for benign nontoxic thyroid disease is an underappreciated complication. In the past, it was common practice for physician s to place most post-hemithyroidectomy patients on prophyl actic thyroid suppression therap y with low-do se levothyroxine. The rationale for this strategy was based on the assumption that the addition of low-dose levothyroxine would prevent recurrence of disease in the remaining thyroid tissue by inhibiting endogenous production of thyroid-stimulating hormone (TSH). A consequence of this practice was that the administration of levoth yroxine prevented physicians from recogni zing those patient s who would have otherwise becom e hypothyroid after hemithyroidectomy.
In more recent years, physicians stopped administering thyroid suppression therapy dur ing the immediate postoperative period. Instead, the new strategy was to follow these patients clinically for signs of recurrence or growth. The emergence of the new trend was based on two developments: ( I) the public ation of data that put into question the efficacy of levothyroxine therapy for pre venting recurrent disease or thyroid growth and (2) a heightened awareness of the morbidity associated with levothyroxine .P One result of thyroid suppression ther apy with levothyroxine is subclinical thyrotoxicosis (subclinical hyperthyroidi sm), defined as the presence of a low TSH level with a normal free thyroxine (FT 4 ) level. Some studies have shown an association between this state and variou s endocrine and cardiac abno rmalities.v'"
With fewer patients being placed on levothyroxine during the immediate postoperative period, it has become easier to ide ntify those who develop hypoth yroidism . Rou tine thyroid function tests obtained as ea rly as I month after surgery may identi fy those patients with subclinica l, as we ll as overt, hyp oth yroidism .
We co nducted a study to identify ce rtain risk fac tors that may place a patient at a higher risk for developing hypothyroidism after hem ithyroid ectom y. Th ese potenti al risk fact ors includ e age, sex, tissue patholo gy characteristics , the size of the thyroid remnant, a history of neck irradi ation , and coexi stin g thyroid autoimmune disea se.
Patients and methods
After obtaining institutional revi ew board approval , we conducted a retrospective chart review of all patients who had underg one a hemithyroidectomy from 1994 through 2003 at Northwestern Mem orial Hospital in Chic ago . We ide ntified 150 such patient s by sea rching a surgical pathology database usin g the search term s hemith yroidectomy and thyroid lobectomy .
Ch arts were reviewed for information on age, sex, serum TSH levels (both preo perative and postoperati ve), final surgical pathology resul ts, the weig ht ofthe resected gland, postoperati ve sy mptoms, a history of neck irradia tion, and coexisting thyroid autoimmune disease. Th e ind ication for surgery was not used as a criterion for patient eligi bility, but we d id excl ude those patients who had a preoperat ive diagn osis of malignancy, hyperth yroidi sm , or hypothyroidism . Oth er exclusion criteria includ ed age les s than 18 ye ars or more than 90 years, the admini stration of postoperative thyroid suppress ion therapy, previ ous use of any medicati on known to alter thyroid hormone or seru m TSH level , a compl etion thyroidectomy within the prev ious 2 years, a lack of appropriate laboratory work , and a lack of follow-up.
A total of 58 pati ent s---44 wom en and 14 men , aged 23 to 75 years (mean 46 .5)-met our eligibility requirements. Their tissue spec imens were sent for routine pathology and analy zed for the presence of inflamm ation, the type of nodular disease, the size of the nodul es, and the surrounding tissue path ology.
An eleva ted se ru m TSH level was used as a marker for hypoth yroidism . All patient s had at least one serum TSH level drawn before surgery and at least one other drawn within 6 weeks after surgery. Serum TSH levels wer e measured by using the standard seru m assay at our institution (ra nge of norm al: 0.4 to 4 .0 ).lIU/ml). Patien ts who were clinicall y asy mptomatic but who had a seru m TSH level greater th an 4 .0 ull.l/ml with a normal Fr 4 1evel were diagnosed as having subclinical hypothyroidism. Overt hypothyroidism was diagnosed in those who had an elevated seru m TSH level and a low Fr 4 level and in those who had symptoms attributable to hypothyroidism. Th e scheduling of serum TSH measur em ent s was based on the known half-life of thyroxin e (T), which is 7 day s, 296 and the response of seru m TSH to changes in the T 41 evel (TSH rises immediately after a drop in T 4I evels). Alth ough study dat a vary, it is ge nerally believed that the TSH level should rise in 4 to 5 weeks if the remaini ng thyroid gland is not produ cing enough T 4 . I J Data analysis was performed with the unp aired Studen t' s t test for p value calcul at ion. 95% con fiden ce intervals (CIs) , means, standa rd deviations, and perce ntages.
Results
There were severa l reasons that only 58 of the 150 pati ent s in our database (38.7 %) met our eligibility requirem ent s. Fir st, during the first 5 years of our study's time fram e, administration ofprophylactic thyroid suppress ion therapy was routin e at our institution .As a result , we had to exclud e 50 patient s (33.3%), and therefore a good deal of our data wa s obtained from surgeries performed from 1999 through 200 3.Another 27 patients ( 18.0%) had undergone acompletion thyroid ectom y with in the previous 2 yea rs, and proper follow -up was lacking in 15 others ( 10.0 %).
Of the 58 study patient s, 14 (24. 1%) had bec om e hypoth yroid postopera tive ly, and the rema ining 44 patients (75.9%) were euthyroid.
Demographic characteristics. There were no statistically significant differen ces between the hypoth yroi d gro up and the euthyroi d group wit h res pect to age (mea n: 47.8 and 46 .8 yr, respecti vely) and sex (distributio n: 3 me n/l l wo me n and II men/33 wom en , respec tive ly).
Pre-andpostoperative TSH levels. Th e mean preoperative serum TSH level in the 14 patient s who had becom e hyp oth yroid was 2.39 ).lIU/ml (range 1.17 to 3.90; 95% CI: 1.53 to 2.94 ). The ir mean postope rati ve level was 14.88 ).lIU/ml (range: 4.80 to 70 .73; 95 % CI: 4.43 to 25 .28) (table I) .
Acomplete thyroid fun ction panel (seru m TSH, Fr 4 , and T 4 measurement s) wa s obt ained fro m 8 of the 14 hypothyroid patient s. Of thes e 8 patient s, 6 had ove rt hyp oth yroidism and 2 had subclinical hypothy roidi sm. Th e patient s with subcli nical hyp oth yroidism were asy mptoma tic, but lab oratory testin g showed a mildl y eleva ted TSH level and a norm al Fr 4 level.
O f the 14 hypoth yroid patients, 7 were diagnosed as such I month postoperati vely, 6 at 2 month s, and the other at 4 mo nths (table I) . Most of these higher TSH levels ranged between 4.80 and 9.62 ull.l/ml (table I) .
In the euth yroid gro up. the mean preoperat ive TSH level was 1.07 ).lIU/ml (range : 0.39 to 2.35; 95% CI : 1.0 I to 1.37). Th e differen ce in preoperat ive TSH levels betw een the hypo-and euthyroid gro ups was statistica lly significant (p < 0.000 I).
All 44 patient s in the euthyroid gro up had at least one se rum TSH level drawn within 6 weeks after surgery. While 34 of them had multiple TSH levels drawn at various times, 10 patient s had only one TSH level drawn, and all 10 of these levels had been drawn at either 5 or 6 weeks postoperative ly (tab le 2). Fourteen of the euthyroid patient s had TSH levels drawn at I and 2 mo nths after surgery; the rema ining 20 euthyroid patients had the last of their T SH levels drawn between 4 mo nths and 2-plus yea rs after surgery .
Tissue path ology. Seven of the 14 hypothyro id patie nts (50 .0%) had a tiss ue diag nosis co nsiste nt with infla mmation (i.e., chro nic lymphocytic thyroi ditis and Hash imoto's thyroid itis), co mpared with only 3 of the 44 euthyroi d patients (6.8%) . The difference was statistica lly significa nt (p < 0.001).
Amo ng the other 7 patients in the hypoth yroid gro up, 4 (28 .6%) had a diag nosis of follicular ade nom a, 2 ( 14.3%) had mul tinodul ar goiter, and I (7. I%) had d iffuse atro phy and scar tissue on the thyroid gland (table I) . Th e patient with atrophy and scar tissue had undergone trea tme nt with radioactive iodine ( 131 1) for multinodul ar go iter disease 2 years earl ier, and she had been euthyroi d prior to hemithyroidectom y. Most of the euthyroid patients had follicular adeno ma (tab le 3). Ot her pathologies included mul tinodular goiter, ade nomatous hyperplasia, and hemorrh agic cysts. Two patients had norm al thyroi d tissue.
T he mean weig ht of the resected tissue in the hypoand eu thyro id groups was 27 .2 and 20 .6 grams, respective ly. Th is d ifference was not sta tistica lly significant (p = O. I662).
Neck irradiation. Only I patien t-a hypothyroid patient-had a history of neck irradiation .
Discussion
Th e usual indication for hem ithyro idectom y is the presence of a si ngle do minant thyroid nodule in a patien t whose fine-need le aspiration findings are suspicious or indeter min ate. Hemit hyroidectomy is also performed on patients with unilateral or bilateral thyroid en large ment, toxic or nont oxic nodul ar thyroid disease, and d iffuse or mul tinodul ar goiter. Beca use only one lobe of the thyroid gland is removed, hem ithyroidectom y is associated with a lower incidence of pos topera tive hypocalcemia and rec urre nt and superior laryngeal nerve injury than is total thyroidectomy.12 Because the rem ain ing lobe is unharmed, most patie nts reta in eno ugh thyroid function to remai n euthyro id. T herefore, hemithyroidecto my is the proced ure of choice for patients who likely have benign pat hology.
Hypothyro idism. Its advan tages not withst and in g , hem ithyroid ectom y may res ult in hypothyroidism , and patients sho uld be made aware of thi s poss ibility. Th e risk factors for hypothyroidism have not been ex tensively stud ied. During our MED LI NE literature searc h, we found that few stud ies of the incidence and risk factors of hypothyroidism afte r thyro id lobectomy have been published in It is sta ndard ca re to treat overt hyp oth yroidism with ho rmone rep laceme nt therap y, but treatm ent guide lines are less definiti ve fo r subclinical hypoth yroid ism . Th e latter has been reported to occ ur sponta neously in 10% of wom en older than 60 ye ars. '? Altho ugh pat ients wi th subcli nical hyp oth yroidism are cl inically asymptom at ic, they have an increased risk of de ve loping a maj ordep ressi ve disorder or mood disord er, an increased left ventr icular hyp ert rophy, and an unfavorabl e lip id profi le.'>" Studies have shown that the treatment of subcl inica l hyp oth yroid ism res ults in a favorab le resp on se in term s of mood affec t and low -density lipop rot ein level s, and man y authors suppo rt thyroid hormon e rep laceme nt therap y in these pa tie nts. IS Thyrotoxicosis. Wh ile proph ylacti c thyroi d suppress ion therapy wa s once thought to be devoid of negat ive health consequences, recent da ta have show n that subcli nica l thyrotox icosis does in fact have so me adverse health effects. It has been show n to negat ively affec t ca lcium balance and decrease bone mineral den sity; increase tot al cho les tero l and low-d ensity lipop rot ein level s and decrease high-densit y lipop rotein level s; and lower the thresh old for depression and other psychiatric disorders." Subclinical thyrotoxicosis is also associated with a three-fol d increase in the risk of atrial fibri llatio n.v' ? Oth er car diac co m plications include increased hea rt ra te, increased left ven tricular mass index, imp aired car diac co ntractility, diastol ic dysfunction, and the induct ion of ec to pic atria l beats or arrythmias. S.9 Th ose who are specifically at risk for adverse effects are elde rly wo me n and pati ent s with a known diagnosis of coronary ar tery disease and/or ischemi c heart disease." Th erefore, give n the lack of substantial evi de nce su pporting the efficacy ofthyroid sup pression therap y in preventing rec urrent thyroid disease, it see ms prudent to fo rgo it as a ro utine strategy after hemithyroid ectom y and to observe patients fo r the need fo r th yroid supple me ntatio n therap y.
Literature review. O ur findi ng that 24 .1% of patient s developed hyp oth yroid ism after undergoin g hem ith yroidec to my for ben ign thyroid disease is co nsiste nt with others 29 8 rep ort ed in the literature. In fac t, Buchanan and Lee reported an identical 24 .1% incid en ce in 200 1. 19 Th ey found that pati ent s with nodular goi te r and elevated th yroid autoantibo dy levels we re sig nifica ntly more likely to becom e hyp oth yroid foll owin g unil ateral thyroid lob ectom y (p < 0 .00 I). They also fo und that patients with elevated th yro id aut oantibod y level s had a significa ntly higher inc ide nce of lymphocytic thyroid itis (p < 0 .00 I). Th ey con cl ude d that an elevated thyroid autoantibo dy level is an ind ep end ent risk fac tor for hypoth yroidi sm . We recogni ze the ro le that thyroid autoa ntibo dy level s may play in the devel opment of postop erati ve hyp othyro idism , but becau se ours was a ret rosp ective study, we we re limit ed by the typ e of data we co uld analyze , and we therefore did not facto r thi s var iabl e into our analysis.
In 1991 , Berglund et al rep orted that the incid ence of hyp oth yroi dism fo llowing surge ry for ben ign nont oxic go iter was 7.4%.13 Th ey fo und a significant correlatio n bet ween the inc ide nce of postop er ati ve hyp oth yroidism and the degree of chron ic lymphocytic thy roi ditis afte r unil ateral surgery (p = 0. 0 16). A year later, Okam oto et al rep ort ed a similar co rre latio n in patient s with Graves ' disease who und erwent subtota l thyroidectom y."
Regardin g other po te ntia l risk factors, we di d not find any significa nt differen ce betw een our tw o groups wit h respect to age, sex, and the we ight of the resected g land . However, we did find that the mean preop erat ive seru m TSH level was significantly higher in the hyp oth yroid Our study, like others, has shown that the presenc e ofcertain factors may place a patient at a higherrisk of developing hypothyroidi sm foll owing hemithyroidectomy. However, as previously mentioned, we do recognize the limitation s of our study, given its retro spective nature. One subject of conjecture is the possibility that some of the hypothyroid patients would have eventually bec ome euthyroid over time as the remaining thyroid tissue compensated for the loss of one lobe. We were unable to determine thi s because all patients who had an elevated serum TSH level postoperatively were immedi ately placed on thyroid replacement therapy, regardless of whether they were symptomatic or not. Con ver sely, we cannot know if the opposite would have occurred. All but I of the 14 hypothyroid patients had been so diagnosed within 2 month s. However, because serum TSH level s were not drawn from all patients at regular intervals, we cannot know if some of the euthyroid patients who were not followed as often eventually would have become hypothyroid. Our postoperative follow-up period wa s only 2-plu s years. An argument could be mad e that at least some of the patients in the euthyroid group might have eventually become hypothyroid.
Despite these limit ations , we beli eve that our findin gs have confirmed the identity of the key risk factors for the development of hypothyroidism durin g the immediate postoperative period following hemithyroidectomy. We intend to conduct future research in this area by mean s of a prospective study.
